News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dendreon Corporation (DNDN) Loss Widens On Provenge Launch Costs



11/4/2010 6:52:30 AM

NEW YORK, Nov 3 (Reuters) - Dendreon Corp (DNDN.O) on Wednesday reported a wider third quarter loss on costs associated with the launch of its new Provenge vaccine for advanced prostate cancer, but the company provided an encouraging forecast for future sales.

Read at BusinessWeek
Read at Reuters
Read at Xconomy


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES